IMCB

IMCB (Gemabank) is a medical company and market leader among stem cell banks in Russia. It offers services in collection, isolation, cryopreservation and storage of PC ICs. It occupies about 44% of the Russian market at the end of 2018 by the number of samples in storage.

P/E

Net profit

P/B

Book value

P/FCF

FCF

Yield

Growth potential

Report period	2017	2018	2019	2020	2021	2022
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Report period	2017	2018	2019	2020	2021	2022
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Report period	2017	2018	2019	2020	2021	2022
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Report period	2017	2018	2019	2020	2021	2022
ROA
ROE
ROS
EBITDA Margin
Operating margin

Ticker	Name	Type	Nominal value	ISIN	Price
GEMA:RM	IMCB	Common share	RUB 0.01	RU000A100GC7	RUB 102

Name	Issue size	Price	Yield
IMCB JSC BO-P01-02 (RUB)	200,000 pcs.	98.52%	14.60%
IMCB JSC BO-P01-01 (RUB)	30,000 pcs.	101.03%	14.34%

All IMCB bonds

Date	Type	Note	Source
17.09.2026 10:00	Meeting of shareholders	Shareholders will decide on the dividends for the first six months of 2026.	disclosure.skrin.ru
25.09.2026 10:00	Dividends	The last day of purchase for receiving dividends RUB 2.74 per common share for 6 month 2026.	www.e-disclosure.ru
12.10.2026 10:00	Dividends	Deadline for payment of dividends RUB 2.74 per common share for 6 month 2026.	www.e-disclosure.ru

IMCB news

13.08.2026

Board of Directors of IMCB recommended that dividends be paid for 6 months 2026 in the amount of ₽2.74 per ordinary share. The last day of the purchase of securities to receive dividends is September 25, 2026. Dividend yield may amount to 2.72%.

Source:

e-disclosure.ru

04.08.2026

Net profit of MMCB under RAS for 6 months of 2026 amounted to ₽49.9 million, which is 37.6% lower compared to ₽80 million in the previous year. Revenue increased by 5.8% to ₽194.4 million, compared to ₽183.7 million a year earlier.

Source:

e-disclosure.ru

02.07.2026

MMCB investing ₽15 million in Orfagenex, a biotechnology startup developing gene therapies for the treatment of rare (orphan) neuromuscular diseases, including spinal muscular atrophy (SMA). So far, ₽10.5 million has been provided. Remaining funds will be allocated by the end of 2026. Funds will be used for preclinical development, scaling up the production...

Source:

artgen.ru

30.06.2026

MMCC has placed 1,217 remaining shares of the additional issue, which were not redeemed under the pre-emptive right, for an OTC placement. The price of the securities is set at ₽116 per share.

Source:

artgen.ru

All IMCB news

General information

Company name	IMCB
Tags	#biotechnology, #innovations of the russia, #stem cells
Sector	Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address	gorod Moskva
Mailing address	119333, g. Moskva, ul. Gubkina, d. 3, korp. 1, etazh 1, pom. 1, komn. 24
CEO	Prihodko Aleksandr Viktorovich
Phone	+7(495) 646-80-76
Website	invest.gemabank.ru
Information disclosure	e-disclosure.ru

IMCB

IMCB balance sheet

IMCB cash flows

IMCB multipliers

IMCB profitability

IMCB shares

IMCB bonds

IMCB expected events